logo-loader
RNS
viewAmryt Pharma PLC

Euronext Growth Dublin Notice

/**/ link{ color: blue }visited{ color: purple } .o{size:595.3pt 841.9pt;margin:148.6pt 56.65pt 42.55pt 2.0cm;}div.o{}table.aw{width:474.9pt;border-collapse:collapse}tr.ap{height:10.65pt}td.as{width:177.2pt;padding:0cm 0cm 0cm 0cm; height:10.65pt}p.ax{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.85pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";color:#464646;font-weight: bold; line-height: 107%; margin-left: 0cm}span.au{line-height:107%;font-family:"Calibri","sans-serif";color:black}td.aq{width:297.7pt;padding:0cm 0cm 0cm 0cm; height:10.65pt}p.ay{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.85pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";color:#464646;margin-left:0cm;line-height:107%}span.ao{font-size:11.0pt;line-height:107%;font-family:"Calibri","sans-serif"; color:black} p.az{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.85pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";color:#464646;font-weight: bold; margin-left: 0cm}span.an{font-family:"Calibri","sans-serif"; color:black}tr.aj{height:12.0pt}td.al{width:177.2pt;padding:0cm 0cm 0cm 0cm; height:12.0pt}td.ak{width:297.7pt;padding:0cm 0cm 0cm 0cm; height:12.0pt}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.85pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";color:#464646;margin-left:0cm;text-align:justify;line-height: 107%}span.ai{line-height:107%;font-family:"Calibri","sans-serif"; color:black}span.bb{color:gray;line-height:107%; font-family:"Calibri","sans-serif";color:black}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.85pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";color:#464646;font-weight: bold; text-align: center}span.ae{font-size:14.0pt;font-family:"Calibri","sans-serif";color:black} p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.85pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";color:#464646;text-align: center}span.be{color:gray;font-size:14.0pt;font-family:"Calibri","sans-serif"; color:black}p.bf{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.85pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";color:#464646;margin-left:0cm}span.aa{font-size:20.0pt; font-family:"Calibri","sans-serif";color:black}span.y{font-size:12.0pt; font-family:"Calibri","sans-serif";color:black}span.bg{color:gray;color: black; font-family: "Calibri","sans-serif"; font-size: 12.0pt; font-weight: bold}span.w{font-size: 12.0pt;font-family:"Calibri","sans-serif";color:black}span.bh{color:gray;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black}span.u{font-size:14.0pt; font-family:"Calibri","sans-serif";color:black}span.t{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} span.s{font-family:"Calibri","sans-serif";color:black}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.85pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";color:#464646;margin-top:0cm;margin-right:0cm;margin-bottom:.15pt; margin-left:-.25pt;text-align:justify;text-indent:-.5pt;line-height:130%}span.r{font-size:8.0pt;line-height:130%;font-family:"Calibri","sans-serif"; color:black}span.p{font-size: 8.0pt;line-height:130%;font-family:"Calibri","sans-serif";color:#0563C1} /**/
RNS Number : 6724M
Euronext Dublin
20 September 2019
 

CORPORATE EVENT NOTICE:

Admission Notice


AMRYT PHARMA PLC

 



LOCATION:

Dublin



DATE:

20th September 2019

MARKET:

Euronext Growth Dublin

 

 

ADMISSION NOTICE

 

Euronext Dublin approves the admission of the undermentioned security to trading on Euronext Growth Dublin.

 

AMRYT PHARMA PLC

2,765,901 Ordinary Shares GBP 0.06

GB00BKB1MS30

Equity

Please note this issuer remains temporarily suspended.

 

 

This announcement has been issued through the Companies Announcement Service of

Euronext Dublin.

 

The present notice and the contents thereof are only provided for information purposes in order to facilitate the fair, orderly and efficient functioning of the market and is not a recommendation to engage in investment activities. The contents of this notice are provided "as is" based on information provided to the market operator without representation or warranty of any kind. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this notice shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator.

 

The Euronext Markets comprise the markets operated by Euronext Amsterdam, Euronext Brussels, Euronext Dublin, Euronext Lisbon, Euronext Paris and Euronext UK Markets, referred to respectively as the Amsterdam, Brussels, Dublin, Lisbon, Paris and London markets, as relevant.

 

Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at https://www.euronext.com/terms-use.

 

© 2019 Euronext N.V.  - All rights reserved


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISELLFIRALIDLIA

Quick facts: Amryt Pharma PLC

Price: 116.5

Market: AIM
Market Cap: £183.74 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016